Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology
Amicus Therapeutics is a biopharmaceutical company focused on developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules to restore or improve biological activity in cells by selectively binding to a misfolded protein caused by a genetic mutation. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical need. Amicus’ lead compound Amigal is in Phase II clinical trials for the treatment of Fabry disease. The company has filed an IND for AT2101 for the treatment of Gaucher disease and has initiated Phase I clinical ( www.amicustherapeutics.com )
Amicus Therapeutics , Inc.
6 Cedar Brook Drive
Cranbury, New Jersey 08512
USA
Tel: (609) 662-2000
Fax: (609) 662-2001